Cerus Endovascular’s portfolio includes multiple CE marked products which will bolster Stryker’s aneurysm treatment business, according to a news release.
“The acquisition of Cerus Endovascular is highly complementary to Stryker’s Neurovascular business, and strengthens our hemorrhagic portfolio globally,” Jim Marucci, president of Stryker’s neurovascular division, said in the release.
